Application of molecular marker SCEL in preparation of products for diagnosing oral squamous cell carcinoma
By using the molecular marker SCEL and its specific recognition antibody immunohistochemistry technology, the problem of insufficient accuracy in the diagnosis and prognosis evaluation of oral squamous cell carcinoma is solved, and a high sensitivity and specific evaluation of the degree of differentiation and prognosis of OSCC is achieved. , provides more accurate diagnosis and prognosis analysis, suitable for rapid diagnosis in hospitals at all levels.
Patent Information
- Application Number
- CN202410955353.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art lacks accuracy and sensitivity in the diagnosis and prognostic evaluation of oral squamous cell carcinoma, and it is difficult to effectively reflect the degree of differentiation and malignancy of the tumor, especially the prognostic evaluation of low-differentiation OSCC.
Using the molecular marker SCEL and its specific recognition antibodies, the expression level of SCEL protein is detected through immunohistochemistry technology, and a kit for diagnosis, grading and prognosis evaluation is developed, and immunoassay is combined with antibodies that specifically recognize SCEL for immunoassay to improve diagnosis and prognosis. Accuracy of the assessment.
By detecting the expression level of SCEL protein, the degree of malignancy and prognosis of OSCC can be more accurately evaluated, personalized treatment plans can be provided, the sensitivity and specificity of diagnosis can be improved, the detection process can be simplified, and the detection process can be suitable for the clinical rapid diagnosis needs and the error of subjective judgment can be reduced.
Smart Images

Figure HDA0004948585150000011 
Figure HDA0004948585150000021 
Figure HDA0004948585150000022
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of a molecular marker SCEL in the preparation of a product for diagnosing oral squamous cell carcinoma. Background Art
[0002] Oral cancer (OSCC) originates from the oral epithelium and is the most common malignant tumor in the maxillofacial region, of which 95% are pathologically classified as oral squamous cell carcinoma. The pathogenesis of oral cancer has not yet been fully elucidated. It is currently believed to be related to risk factors such as long-term smoking and drinking, poor oral hygiene, long-term foreign body stimulation, and chronic oral lesions. Oral cancer is invasive, prone to early lymph node metastasis, lacks clinical and radiological manifestations, and often has local recurrence. Multiple factors have resulted in a 5-year overall survival rate of only 50% for oral cancer.
[0003] At present, the diagnosis of OSCC mainly relies on pathological examination. Traditionally, hematoxylin-eosin (H&E) staining is used to observe the basic morphological information of cells and tissues, but there are certain subjectivity and limitations in evaluating tumor grade and prognosis. The degree of differentiation of the tumor is closely related to its grade and prognosis. The World Health Organization divides OSCC into three grades according to the degree of similarity between tumor cells and normal cells: well-differentiated, moderately differentiated, and poorly differentiated. Well-differentiated OSCC consists of tumor cells that look similar to normal squamous cells (also known as grade 1). Moderately differentiated OSCC consists of tumor cells with certain atypia, but they can still be identified as squamous cells (also known as grade 2). Poorly differentiated OSCC is mainly composed of immature cells, showing a large number of nuclear divisions and atypia (also known as grade 3). The lower the degree of differentiation, the higher the malignancy of the tumor, which often means a worse prognosis. IHC examination provides more detailed molecular level information by detecting specific protein markers, helping doctors to more accurately judge the biological behavior and development trend of the tumor. Therefore, in recent years, immunohistochemistry (IHC) technology has been widely used in the diagnosis and prognosis evaluation of oral cancer. However, the commonly used protein markers are still insufficient in sensitivity and specificity, and it is difficult to fully reflect the differentiation and malignant transformation of tumors. Therefore, there is an urgent need to find new and more reliable markers to improve the diagnosis and prognosis assessment of oral cancer. SCEL is the cornified membrane precursor of terminally differentiated keratinocytes, which plays an important role in the differentiation process of cells. There are currently no reports on the diagnosis and prognosis of SCEL in OSCC. Summary of the invention
[0004] In view of the technical problems existing in the above-mentioned prior art, the present invention provides a molecular marker SCEL for use in the preparation of a product for diagnosing oral squamous cell carcinoma, with the purpose of discovering that the molecular marker SCEL can not only be used to diagnose OSCC, but also analyze the degree of differentiation and prognosis of OSCC. At the same time, an antibody that specifically recognizes SCEL is developed, and the antibody that specifically recognizes SCEL can be used to diagnose OSCC, and can analyze the degree of differentiation and prognosis of OSCC, effectively improving the ability to diagnose and evaluate the prognosis of oral squamous cell carcinoma, and solving the problem that the method for judging the degree of differentiation of oral cancer in the prior art lacks accuracy, is cumbersome and highly subjective.
[0005] In order to achieve the above object, the specific scheme of the present invention is as follows:
[0006] Application of the molecular marker SCEL in the preparation of reagents or kits for diagnosis, grading and prognosis evaluation of oral squamous cell carcinoma.
[0007] Furthermore, the amino acid sequence of the molecular marker SCEL is shown in SEQ.ID.No.1.
[0008] A kit for preparing a diagnosis, grading and prognosis evaluation of oral squamous cell carcinoma, the kit comprising components for detecting the expression level of SCEL, wherein the components for detecting the expression level of SCEL include antibodies that specifically recognize human SCEL.
[0009] Furthermore, the components for detecting the expression level of SCEL also include reagents for immunoassay, neutral buffered formalin fixative, primary antibody diluent, PBS buffer, endogenous peroxidase blocker, enzyme-labeled goat anti-mouse / rabbit IgG polymer, DAB substrate solution and neutral resin.
[0010] Furthermore, the concentration of the neutral buffered formalin fixative is 10%, and the dilution multiple of the primary antibody diluent is 1:350.
[0011] Furthermore, the sequence of the antibody that specifically recognizes SCEL is shown in SEQ.ID.No.2.
[0012] Furthermore, the antibody that specifically recognizes SCEL is a monoclonal antibody or a polyclonal antibody, and the monoclonal antibody or the polyclonal antibody is prepared against the whole or part of the amino acid sequence of the human SCEL receptor.
[0013] Advantages of the present invention
[0014] 1. The present invention provides an application of the molecular marker SCEL in the preparation of a product for diagnosis, grading, and prognosis evaluation of oral squamous cell carcinoma. The molecular marker SCEL is analyzed by immunohistochemistry using an anti-human SCEL antibody. The molecular marker SCEL is highly expressed in adjacent oral epithelial tissues, while its expression is significantly reduced or absent in OSCC tissues. Therefore, the malignancy of OSCC is evaluated and the prognosis evaluation is enhanced by detecting the expression level of the molecular marker SCEL protein. The molecular marker SCEL can assist doctors in better evaluating the prognosis of patients and help formulate a more appropriate treatment plan.
[0015] 2. The kit of the present invention adopts a highly specific SCEL protein antibody, which can accurately identify and bind to the target protein, ensure the high sensitivity and specificity of the test results, and can be widely used in the detection of various types of OSCC samples. It has important reference value for judging the degree of differentiation of OSCC and formulating personalized treatment plans, and the detection process is simple, and the results can usually be obtained within 1-2 days, which is suitable for clinical rapid diagnosis needs. The kit has the advantages of high accuracy, high sensitivity and specificity, simple operation, rapid detection and strong practicality, and is suitable for hospitals and laboratories at all levels. The kit detects the expression level of SCEL protein by immunohistochemistry, and by directly observing the protein expression in the tissue, it can more accurately diagnose OSCC, judge its degree of differentiation, and reduce the error of subjective judgment. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The immunohistochemical results of SCEL of the present invention in paracancerous tissues and OSCC tissues are shown.
[0017] Figure 2 Figure 3 is the ROC curve of SCEL of the present invention in paracancerous tissue and OSCC tissue.
[0018] Figure 3 The figure shows the immunohistochemical results of SCEL of the present invention in paracancerous tissues and OSCC tissues.
[0019] Figure 4 The ROC curve of SCEL of the present invention in OSCC tissues with high, medium and low differentiation is shown in FIG. DETAILED DESCRIPTION
[0020] The present invention is further explained below in conjunction with the accompanying drawings and specific embodiments. It should be noted that the specific embodiments are not intended to limit the scope of rights of the present invention.
[0021] like Figures 1 to 4 As shown, in this specific embodiment, the molecular marker SCEL is applied in the preparation of a product for diagnosing oral squamous cell carcinoma, and the specific process is as follows:
[0022] Example 1: Sample collection
[0023] A total of 106 pairs of OSCC tissues and corresponding adjacent cancer tissues (>5 cm from the tumor edge) were collected from September 2019 to December 2022 by the Affiliated Stomatological Hospital of Guangxi Medical University, including 56 cases of well-differentiated OSCC, 26 cases of moderately differentiated OSCC, and 24 cases of poorly differentiated OSCC.
[0024] The inclusion criteria for OSCC tissue cases were: (1) patients diagnosed with oral squamous cell carcinoma (diagnosed by two senior pathologists); (2) patients who had not received any chemoradiotherapy, targeted drug therapy, or immunotherapy before surgery; and (3) patients with complete clinical information.
[0025] Exclusion criteria were: (1) patients who refused to participate in the experiment; (2) patients with unknown diagnosis; and (3) patients with other malignant tumors or systemic diseases.
[0026] Example 2: Immunohistochemistry method
[0027] The antibody that specifically recognizes SCEL in this embodiment is SCEL Polyclonal Antibody PA5-59082 produced by Thermo Fisher Scientific, USA, and the methods for preparing the antigen, injecting the antigen, immune monitoring, collecting the antibody and purifying the antibody are all known. The amino acid sequence of the molecular marker SCEL is shown in SEQ.ID.No.1. The immunogenic sequence specific to the primary antibody of the antibody that specifically recognizes SCEL is shown in SEQ.ID.No.1.
[0028] The steps of the immunohistochemical method are as follows:
[0029] (1) Fixation: OSCC tissue samples were fixed with 10% neutral buffered formalin for 24 hours.
[0030] (2) Embedding and sectioning: The fixed tissue samples were dehydrated, transparentized, and embedded in paraffin, with a section thickness of 4 μm. After sectioning, the samples were placed in an oven at 58°C for 3 hours.
[0031] (3) Dewaxing and hydration: After baking, the slices were dewaxed in xylene four times, each time for 8 min. The residual liquid on the slices was drained and then hydrated in graded alcohol with concentrations from high to low (100%, 95%, 85%, 75%).
[0032] (4) Antigen repair: Place the slices in an antigen repair box, and mix 150 ml of distilled water and 3 ml of EDTA antigen repair solution (pH = 9) in the box. Add appropriate amount of water to the pot, place the repair box upright in the pot, close the lid and heat. Stop heating after the repair solution boils for 5 minutes. When the pressure in the pot drops, take out the repair box and gradually cool it to room temperature. Soak the slices in fresh PBS buffer for 2 minutes.
[0033] (5) Block endogenous peroxidase: Drain the remaining liquid on the slices and place them on a wet box. Use an IHC pen to draw a frame around the edge of the tissue to prevent loss of reagents. Add an endogenous peroxidase blocker to cover the entire tissue. Cover the wet box and incubate for 10 minutes, then immerse the slices in fresh PBS buffer for 5 minutes. Repeat 3 times.
[0034] (6) Primary antibody incubation: Centrifuge the primary antigen solution, divide it into EP tubes and store it in a -20℃ refrigerator, with each portion not less than 10μL. Dilute the antibody with primary antibody diluent. The dilution multiple of SCEL is 1:350. Drain the residual liquid on the slices, add the primary antibody dropwise, and let it cover the entire tissue. Cover the wet box, incubate the slices at 4℃ overnight, take them out the next day, return to room temperature, and immerse them in PBS buffer for 5 minutes. Repeat 3 times.
[0035] (7) Secondary antibody incubation: Drain the remaining liquid on the slices and add biotin-labeled goat anti-mouse / rabbit IgG polymer to cover the entire tissue. Cover the wet box and incubate for 10 minutes. Then immerse the slices in fresh PBS buffer for 5 minutes. Repeat 3 times.
[0036] (8) Color development: Prepare DAB substrate solution (1X). Mix 1 ml of substrate solution and 50 μL of DAB (20X) in a light-proof bottle. Drain the remaining liquid on the slices, place the slices on a white plate, add appropriate amount of DAB solution to cover the entire tissue, incubate at room temperature, and immediately rinse the slices uniformly to stop color development after the positive control develops.
[0037] (9) Restaining: Immerse the sections in a hematoxylin staining tank for 30-60 seconds and rinse for 1 minute.
[0038] (10) Differentiation and anti-blueing: Immerse the sections in 0.5% hydrochloric acid alcohol for 3-5 seconds and rinse for 1 minute; then immerse them in a saturated lithium carbonate solution for 2-3 minutes and rinse for 1 minute.
[0039] (11) Dehydration and transparency: The sections were dehydrated in graded alcohol with concentrations from low to high (75%, 85%, 95%); then transparentized in fresh xylene.
[0040] (12) Sealing: Place the slices in a 58°C oven for 5 min. After drying, add a drop of neutral resin, seal the slices with a coverslip, and observe under a microscope after air drying.
[0041] Example 3 Detection of SCEL protein expression level
[0042] (1) Sample processing and immunohistochemical staining: Human OSCC tissue samples to be tested were collected and immunohistochemical staining was performed according to the method of Example 2.
[0043] (2) Observation of SCEL protein expression level: Observe and take pictures under a microscope to record the expression intensity of SCEL protein. First, observe OSCC cells and / or normal oral squamous cells under a low-power microscope (100×), and then observe under a high-power microscope (400×). Ten fields of view were randomly selected for observation.
[0044] (3) H score: Two experienced pathologists independently evaluated the immunohistochemical staining results and performed semi-quantitative analysis to determine the H score of SCEL protein. The evaluation criteria for staining intensity are as follows: negative or weak (no staining or very weak staining), moderate (moderate staining), and strong (strong staining), corresponding to the numbers 1, 2, and 3, respectively. The percentage of positive tumor cells on each section refers to the proportion of tumor cells that are positively stained by SCEL in all tumor cells (ranging from 0% to 100%). The H score (ranging from 0 to 300) is obtained by multiplying the above two results and calculating their average.
[0045] Example 4 Analysis of SCEL protein expression levels
[0046] 1. Analysis of the difference in SCEL expression between OSCC tissues and adjacent tissues
[0047] SCEL showed strong positive expression in adjacent normal oral epithelial tissue (median H score 190, 85-300), while the expression was significantly weakened or absent in OSCC tissue (median H score 80, 0-195), and the difference was statistically significant (p<0.0001). Figure 1 shown.
[0048] 2. ROC curve analysis of SCEL expression in OSCC tissues and adjacent tissues
[0049] When the ROC curve analysis of SCEL expression in 106 pairs of OSCC tissues and adjacent normal oral epithelial tissues was performed, the results showed that SCEL had a high diagnostic accuracy in distinguishing cancerous and non-cancerous tissues. The area under the curve (AUC) of the ROC curve was 0.8940 (CI: 0.8418-0.9461) (P<0.001), which indicated that SCEL expression had a high ability to distinguish OSCC tissues from adjacent normal tissues. Figure 2 shown.
[0050] 3. Differential analysis of SCEL expression in highly, moderately and poorly differentiated OSCC tissues
[0051] There were significant differences in the expression of SCEL protein in oral cancers of different degrees of differentiation (P<0.0001). In patients with well-differentiated OSCC, the median h-score of SCEL was 100 (range 30-180), which was significantly higher than the h-scores of patients with moderate differentiation (median 60, range 0-120) and poor differentiation (median 20, range 0-105). This indicates that as the degree of tumor differentiation decreases, the expression level of SCEL significantly decreases. Therefore, by detecting the expression level of SCEL protein, it can be used as a reliable indicator of the degree of differentiation of oral cancer, such as Figure 3 shown.
[0052] 4. ROC curve analysis of SCEL expression in high, medium and low differentiated OSCC tissues
[0053] The ROC curve analysis of SCEL expression in well-differentiated, moderately differentiated and poorly differentiated oral squamous cell carcinoma (OSCC) tissues and adjacent normal tissues was performed to evaluate its effectiveness in distinguishing OSCC with different degrees of differentiation from adjacent tissues. The area under the curve (AUC) of the ROC curve of SCEL in well-differentiated OSCC was 0.9004 (CI: 0.8399-0.9608) (P<0.0001), showing a very high ability to distinguish. The AUC of the ROC curve of SCEL in moderately differentiated OSCC was 0.8121 (CI: 0.6897-0.9345) (P=0.0001), indicating its effectiveness in distinguishing moderately differentiated OSCC from adjacent tissues. The AUC of the ROC curve of SCEL between poorly differentiated OSCC and adjacent normal tissues was 0.8872 (CI: 0.7819-0.9924) (P<0.0001), showing its good ability in distinguishing poorly differentiated OSCC from adjacent tissues. These results indicate that SCEL expression has significant diagnostic value in distinguishing OSCC with different degrees of differentiation from adjacent normal tissues, and can effectively distinguish high, medium, and low-differentiated OSCC tissues from adjacent normal tissues. This further supports the clinical application potential of SCEL as an OSCC grading marker and suggests that SCEL expression levels are associated with the prognosis of OSCC, such as Figure 4 shown.
[0054] The above analysis of the expression level of SCEL protein indicated that SCEL protein is strongly expressed in the normal differentiated squamous epithelium of the oral cavity and therefore has the potential to become a molecular marker.
Claims
1. Application of the molecular marker SCEL in the preparation of reagents or kits for diagnosis, grading, and prognosis evaluation of oral squamous cell carcinoma.
2. The use according to claim 1, characterized in that: The amino acid sequence of the molecular marker SCEL is shown in SEQ.ID.No.
1.
3. A kit for preparing a diagnosis, grading, and prognosis evaluation of oral squamous cell carcinoma, characterized in that: The kit comprises components for detecting the expression level of SCEL, and the components for detecting the expression level of SCEL include antibodies that specifically recognize human SCEL.
4. The kit according to claim 3, characterized in that The components for detecting the expression level of SCEL also include reagents for immunodetection, neutral buffered formalin fixative, primary antibody diluent, PBS buffer, endogenous peroxidase blocker, enzyme-labeled goat anti-mouse / rabbit IgG polymer, DAB substrate solution and neutral resin.
5. The kit according to claim 4, characterized in that The concentration of the neutral buffered formalin fixative is 10%, and the dilution multiple of the primary antibody diluent is 1:
350.
6. The kit according to claim 3, characterized in that The sequence of the antibody that specifically recognizes SCEL is shown in SEQ.ID.No.
2.
7. The kit according to claim 3, characterized in that The antibody that specifically recognizes SCEL is a monoclonal antibody or a polyclonal antibody, and the monoclonal antibody or the polyclonal antibody is prepared against the whole or part of the amino acid sequence of the human SCEL receptor.
